Metabolome profile comparison of cisplatin sensitive and resistant in ovarian epithelial cells by magnetic resonance spectroscopy spectroscopy

authors:

avatar Ziba Akbari , avatar A. li Awsat Mellati , avatar Amir Amanzadeh , avatar Aboalfazl Nazarian , avatar Zahra Zamani , avatar Mohammad Arjmand ORCID , *

Koomesh: Vol.17, issue 4; 895-902
published online: September 28, 2016
article type: Research Article
received: July 02, 2015
accepted: December 03, 2015

how to cite: Akbari Z, Awsat Mellati A L, Amanzadeh A, Nazarian A, Zamani Z, et al. Metabolome profile comparison of cisplatin sensitive and resistant in ovarian epithelial cells by magnetic resonance spectroscopy spectroscopy. koomesh. 2016;17(4):e151182. 

Abstract

Introduction: Epithelial ovarian carcinoma is considered to be the most lethal gynecological malignancy in women and accounts for more than 85% of ovarian carcinomas. The chemotherapeutical treatment of choice is cisplatin. However, long-term use of this drug mostly results in drug resistance phenomenon. Metabolomics, is a highly resourceful technique, which acts promising in monitoring of tumor growth. Proton nuclear magnetic resonance spectroscopy (1H-NMR) is a non-invasive and high reproducible technique used in metabolomics. In the present investigation, we tried to find biochemical pathways and their metabolic alterations in epithelial cells of ovarian carcinoma and study the mechanism involved in cisplatin drug resistance. Materials and Methods: The cell lines A2780 and A2780CP were prepared. Methanol-chloroform-water extraction was performed.The hydrophilic layer were collected separately and cell1H-NMR spectroscopy were applied on a Bruker spectrometer operating at 400 MHz. After processing the data, outlier metabolites were identified and their biochemical pathways were worked out by Metaboanalyst and Human Metabolome Database. Results: In the present study, the main altered metabolites were fucose, sorbitol, mannitol, mannose, rhamnose, glycerol, galactonite, alpha lactose, myo-inositol and melibiose. The biochemical pathway enrichment analysis showed that galactose, fructose and mannose metabolism was the most prominent altered pathways. Conclusion: Our results disclose that cisplatin resistance results from alteration in carbohydrates metabolites and their pathways. However, further study is needed to confirm these findings

References

  • 1.

    Metzger-Filho O, Moulin C, D'Hondt V. First-line systemic treatment of ovarian cancer: a critical review of available evidence and expectations for future directions. Curr Opin Oncol 2010; 22: 513-520.

  • 2.

    Akbari ME KM. Incidence, mortality and burden of cancers in Iran. Cancer Res Shahid Beheshti Univ Med Sci 2008: 95-125. (Persian).

  • 3.

    Kurman RJ, Shih Ie M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008; 27: 151-160.

  • 4.

    Ronconi L, Giovagnini L, Marzano C, Betto F, Graziani R, Pilloni G, Fregona D. Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity. Inorg Chem 2005; 44: 1867-1881.

  • 5.

    Lee RX, Li QQ, Reed E. Beta-elemene effectively suppresses the growth and survival of both platinum-sensitive and -resistant ovarian tumor cells. Anticancer Res 2012; 32: 3103-3113.

  • 6.

    Lehnhardt FG, Bock C, Rhn G, Ernestus RI, Hoehn M. Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation. NMR Biomed 2005; 18: 371-382.

  • 7.

    Gottschalk M, Ivanova G, Collins DM, Eustace A, O'Connor R, Brougham DF. Metabolomic studies of human lung carcinoma cell lines using in vitro (1)H NMR of whole cells and cellular extracts. NMR Biomed 2008; 21: 809-819.

  • 8.

    Lodi A, Ronen SM. Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment. PLoS One 2011; 6: e26155.

  • 9.

    Liu G, Hale GE, Hughes CL. Galactose metabolism and ovarian toxicity. Reprod Toxicol 2000; 14: 377-384.

  • 10.

    Xu YK, Ng WG, Kaufman FR, Lobo RA, Donnell GN. Galactose metabolism in human ovarian tissue. Pediatr Res 1989; 25: 151-155.

  • 11.

    Forges T, Monnier-Barbarino P, Leheup B, Jouvet P. Pathophysiology of impaired ovarian function in galactosaemia. Hum Reprod Update 2006; 12: 573-584.

  • 12.

    Ferretti A, D'Ascenzo S, Knijn A, Iorio E, Dolo V, Pavan A, Podo F. Detection of polyol accumulation in a new ovarian carcinoma cell line, CABA I: a1H NMR study. Br J Cancer 2002; 86: 1180-1187.

  • 13.

    Bando T, Fujimura M, Kasahara K, Shibata K, Shirasaki H, Heki U, et al. Exposure to sorbitol induces resistance to cisplatin in human non-small-cell lung cancer cell lines. Anticancer Res 1996; 17: 3345-3348.

  • 14.

    Liu H, Huang D, McArthur DL, Boros LG, Nissen N, Heaney AP. Fructose induces transketolase flux to promote pancreatic cancer growth. Cancer Res 2010; 70: 6368-6376.

  • 15.

    Poliakov E, Managadze D, Rogozin IB. Generalized portrait of cancer metabolic pathways inferred from a list of genes overexpressed in cancer. Genet Res Int 2014; 2014: 646193.

  • 16.

    Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013; 4: e532.

  • 17.

    Piccart M, Lamb H, Vermorken JB. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Annal Oncol 2001; 12: 1195-1203.

  • 18.

    Tatsumura T, Sato H, Mori A, Komori Y, Yamamoto K, Fukatani G, Kuno S. Clinical significance of fucose level in glycoprotein fraction of serum in patients with malignant tumors. Cancer Res 1977; 37: 4101-4103.

  • 19.

    Thompson S, Dargan E, Turner GA. Increased fucosylation and other carbohydrate changes in haptoglobin in ovarian cancer. Cancer Lett 1992; 66: 43-48.

  • 20.

    Kudo T, Nakagawa H, Takahashi M, Hamaguchi J, Kamiyama N, Yokoo H, et al. N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma. Mol Cancer 2007; 6: 32.

  • 21.

    Pochechueva T, Jacob F, Fedier A, Heinzelmann-Schwarz V. Tumor-associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches. Metabolites 2012; 2: 913-939.

  • 22.

    Hu Z, Gao J, Zhang D, Liu Q, Yan L, Gao L, et al. High expression of Lewis y antigen and CD44 is correlated with resistance to chemotherapy in epithelial ovarian cancers. PloS One 2013; 8: e57250.